Shire drops Dynepo but raises revenue guidance
This article was originally published in Scrip
Executive Summary
Shireis to drop its anaemia treatment Dynepo (epoetin delta) after the drug performed poorly in the second quarter, earning just $7 million. Dynepo was launched in Europe in March last year but has continued to disappoint, making just $14 million last year and another $14 million in the first half of this year. Shire attributed the discontinuation to significant reductions in prices following the entry of bio-similars to the market. The company recorded charges of $150 million as a result of the move, but said that it would redirect its resources to the launches of products such as Mezavant (mesalazine) and Daytrana (methylphenidate transdermal system) in Europe.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.